

1954-433
MC:jdh

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Don J. DIAMOND)
Serial No. To Be Assigned) Examiner: Padmashri Ponnaluri
Filed: August 20, 2003) Group Art Unit: 1639
FOR CTL BEFORE ANALYSIS)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith Form PTO-1449 listing publications that the Office may wish to consider in examination of the subject application.

Pursuant to 1.98(d), copies of the references are not included because they were previously submitted to the Office in prior application Serial No. 09/692,325, filed October 20, 2000.

Respectfully submitted,

By 

Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040














Enclosure(s):
PTO-1449 Form (Five Sheets)

1954-433.ids.wpd

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>			
				Application Number	10/643888 10/643888		
				Filing Date	8/20/03 8/20/03		
				First Named Inventor	Don J. DIAMOND		
				Group Art Unit	1645 1645		
				Examiner Name	MINNIFIELD MINNIFIELD		
Sheet	1	of	5	Attorney Docket Number	1954-433		
U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code (if known)				
<i>MM</i>	AA	6,156,317		DIAMOND et al.	Dec. 5, 2000		
<i>MM</i>	AB	6,074,645		DIAMOND et al.	Jun. 13, 2000		
<i>MM</i>	AC	5,405,940		BOON et al.	Apr. 11, 1995		
<i>MM</i>	AD	5,248,768		LUSSENHOP et al.	Sep. 28, 1993		
<i>MM</i>	AE	4,689,225		PEREIRA	Aug. 25, 1987		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number	Kind Code (if known)			
<i>MM</i>	AF	PCT	94/00150		City of Hope	Jan. 6, 1994	
Examiner Signature	<i>MM Minnifield</i>				Date Considered	4-18-05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/643888 10/643888
				Filing Date	8/20/03 8/20/03
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645 1645
				Examiner Name	Redacted MINNIFIED
Sheet	2	of	5	Attorney Docket Number	1954-433
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
	AG	ALEXANDER et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," Immunity 1:751-761, December 1994.			
	AH	BORYSIEWICZ et al., "Human Cytomegalovirus-Specific Cytotoxic T Cells," J. Exp. Med 168:919-931, September 1988.			
	AI	BROUWENSTIJN et al., "Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma," Journal of Immunotherapy 21(6):427-434, 1998.			
	AJ	CARRUTH et al., "An Algorithm for Evaluating Human Cytotoxic t Lymphocyte Responses to Candidate AIDS Vaccines," Aids Research and Human Retroviruses 15(11):1021-1034, 1999.			
	AK	CHUJOH et al., "The role of anchor residues in the binding of peptides to HLA-A*1101 molecules," Tissue Antigens 52:501-509, 1998.			
	AL	D'AMARO et al., "A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs," Human Immunology 43:13-18, 1995.			
	AM	DEL VAL et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," Cell 66:1145-1153, September 20, 1991.			
	AN	DEL VAL et al., "Protection Against Lethal Cytomegalovirus Infection by a Recombinant Vaccine Containing a Single Nonameric T-Cell Epitope," Journal of Virology 65(7):3641-3646, July 1991.			
	AO	DIAMOND et al., "Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection," Blood 90(5):1751-1767, September 1, 1997.			
	AP	DRIJFHOUT et al., "Detailed Motifs for peptide Binding to HLA-A*0201 Derived from Large Random Sets of Peptides Using a Cellular Binding Assay," Human Immunology 43:1-12, 1995.			
	AQ	ELLIS et al., "Chapter 29, "New Technologies for Making Vaccines", pp. 568-575.			
	AR	FALK et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351:290-296, May 23, 1991.			
Examiner Signature				Date Considered	4-18-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/643888
				Filing Date	8/20/03
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
Examiner Name				MINNIFIELD	
Sheet	3	of	5	Attorney Docket Number	1954-433
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the journal item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
M	AS	FREMONT et al., "Crystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2K ^b ," Science 257:919-927, August 14, 1992.			
M	AT	GÖNCZÖL et al., "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate," Vaccine 13(12):1080-1085, 1995.			
M	AU	GREENBERG et al., "Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded <i>in Vitro</i> ," Annals of the New York Academy of Sciences (Antigen and Clone-Specific Immunoregulation) 636:184-195, 1991.			
M	AV	GUNDLACH et al., "Specificity and Degeneracy of Minor Histocompatibility Antigen-Specific MHC-Restricted CTL," J. Immunol. 156:3645-3651, 1996.			
M	AW	HEMMER et al., "Cutting Edge: Predictable TCR Antigen Recognition Based on Peptide Scans Leads to the Identification of Agonist Ligands with No Sequence Homology," J. Immunology 160:3631-3636, 1998.			
M	AX	KAWASHIMA et al., "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," Human Immunology 59:1-14, 1998.			
M	AY	KHATTAB et al., "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes," J. Med. Virol. 52:68-76, 1997.			
M	AZ	LAROSA et al., "Development of <i>In Vitro</i> Stimulation (IVS) Protocol to Measure CMV Specific CTL Activity Using HLA-Restricted Specific Ctl Epitopes," Blood 92(10 -suppl. 1):518a, 1998 (Abstract 2129).			
M	BA	LEGGATT et al., "The Importance of Pairwise Interactions Between Peptide Residues in the Delineation of TCR Specificity," J. Immunology 161:4728-4735, 1998.			
M	BB	LIPFORD et al., "Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6," Immunology 84:298-303, 1995.			
M	BC	MADDEN et al., "The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the Conformations of Five Viral Peptides Presented by HLA-A2," Cell 75:693-708, November 19, 1993.			
Examiner Signature	N M Minnifield			Date Considered	4-18-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/643888
				Filing Date	8/20/03
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	MINNIFIELD
Sheet	4	of	5	Attorney Docket Number	1954-433
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
m	BD	MCLAUGHLIN-TAYLOR et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8 ⁺ Virus-Specific Cytotoxic T Lymphocytes," J. Med. Virol. 43:103-110, 1994.			
m	BE	NIJMAN et al., "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes," Eur. J. Immunol. 23:1215-1219, 1993.			
m	BF	ONO et al., "Alterations in TCR-MHC Contacts Subsequent to Cross-Recognition of Class I MHC and Singly Substituted Peptide Variants," J. Immunol. 161:5454-5463 (1998).			
m	BG	OSEROFF et al., "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses," Vaccine 16(8):823-833, 1998.			
m	BH	PANDE et al., "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in <i>Escherichia coli</i> ," Virology 182:220-228, 1991.			
m	BI	PARKHURST et al., "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues," J. Immunol. 157:2539-2548, 1996.			
m	BJ	RAMMENSEE et al., "MHC ligands and peptide motifs: first listing," Immunogenetics 41:178-228, 1995.			
m	BK	RAMMENSEE et al., "Peptides Naturally Presented by MHC Class I Molecules," Annu. Rev. Immunol. 11:213-44, 1993.			
m	BL	RASMUSSEN, "Immune Response to Human Cytomegalovirus Infection," Current Topics in Microbiology and Immunology 154:222-254, 1990.			
m	BM	SCHULZ et al., "Peptide-induced antiviral protection by cytotoxic T cells," Proc. Natl. Acad. Sci. USA 88:991-993, February 1991.			
m	BN	SETTE et al., "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," Molecular Immunol. 31(11):813-822, 1994.			
m	BO	SETTE et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," J. Immunol. 153:5586-5592, 1994.			
m	BP	VALMORI et al., "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," J. Immunol. 161:6956-6962, 1998.			
Examiner Signature		N M Minnifield		Date Considered	4-18-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	██████████ 10/643888
				Filing Date	██████████ 8/20/03
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	██████████ 1645
				Examiner Name	██████████ MINNIFIELD
Sheet	5	of	5	Attorney Docket Number	1954-433

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
<i>mm</i>	BQ	VIERBOOM et al., "Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-Induced Tumors Expressing the Wild-Type Epitope," J. Immunotherapy 21(6):399-408, 1998.	
<i>mm</i>	BR	WENTWORTH et al., "In Vitro Induction of Primary, Antigen-Specific CTL From Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," Molecular Immunology 32(9):603-612, 1995.	
<i>mm</i>	BS	WILLS et al., "The Human Cytotoxic T-Lymphocyte (CTL) Response to Cytomegalovirus is Dominated by Structural Protein pp65: Frequency, Specificity, and T-Cell Receptor Usage of pp65-Specific CTL," J. of Virol. 70(11):7569-7579, Nov. 1996.	
<i>mm</i>	BT	WILSON et al., "Immunogenicity. I. Use of peptide Libraries to identify Epitopes that Activate Clonotypic CD4 ⁺ T Cells and induce T Cell Responses to Native peptide Ligands," J. Immunol. 163:6424-6434, 1999.	
<i>mm</i>	BU	ZEH III et al., "Flow-Cytometric Determination of Peptide-Class I Complex Formation Identification of p53 Peptides That Bind to HLA-A2," Human Immunology 39:79-86, 1994.	
<i>mm</i>	BV	HEMMER et al., "The Use of Soluble Synthetic Peptide Combinatorial Libraries to Determine Antigen Recognition of T Cells," J. Peptide Res., 52:338-345, 1998.	
<i>mm</i>	BW	HIEMSTRA et al., "Definition of Natural T Cell Antigens With Mimicry Epitopes Obtained From Dedicated Synthetic Peptide Libraries ¹ ," J. Immunol., 161:4078-4082, 1998.	
<i>mm</i>	BX	BLAKE et al., "Use of Combinatorial Peptide Libraries to Construct Functional Mimics of Tumor Epitopes Recognized By MHC Class...", J. Exp. Med., 184:121-130, 1996.	
<i>mm</i>	BY	PINILLA et al., "Rapid Identification of High Affinity Peptide Ligands Using Positional Scanning...", BioTechniques, 13(6):901-905, 1992.	
<i>mm</i>	BZ	SANDBERG et al., "Recognition of the Major Histocompatibility Complex...", J. Exp. Med., 189 (6):883-893, 1999.	
<i>mm</i>	CA	SOARES et al., "Differential Activation of T Cells by Natural Antigen Peptide Analogues...", The Journal of Immun., 160:4768-4775, 1998.	
<i>mm</i>	CB	UDAKA et al., "Decrypting the Structure of Major Histocompatibility Complex...", J. Exp. Med., 181:2097-2108, 1995.	

Examiner Signature	<i>N M Minnifield</i>	Date Considered	4-18-05
-----------------------	-----------------------	--------------------	---------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/643,888
Applicant : Don J. DIAMOND
Filed : August 20, 2003
TC/A.U. : 1645
Examiner : Nita M. Minnifield

Docket No. : 1954-433
Customer No. : 06449
Confirmation No. : 4642
Title : CTL EPITOPE ANALOGS

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:


Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. The Lang et al. reference (US 2004/0209314) is cited as the equivalent to FR 2798128, filed September 6, 1999.


Pursuant to 37 C.F.R. § 1.17(p), a check for \$180.00 is enclosed. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 02-2135. An additional copy of this document is enclosed.

01/21/2005 AWONDAF1 00000031 022135 10643888
01 FC:1806 180.00 DA

Respectfully submitted,

By


Martha Cassidy
Attorney for Applicants
Registration No. 44/066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				<i>Complete if Known</i>	
				Application Number	10/643,888
				Filing Date	August 20, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	Nita M. Minnifield
				Confirmation No.	4642
Sheet	1	of	2	Attorney Docket Number	1954-433











U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
<i>MM</i>		5,635,363		Altman et al.	06/03/1997
<i>MM</i>		6,251,399		Diamond et al.	06/26/2001
<i>MM</i>		6,562,345		Diamond	05/03/2003
<i>MM</i>		6,726,910		Diamond	10/09/2003
<i>MM</i>		2004/0209314		Lang et al.	10/21/2004

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
Examiner Signature	<i>NM Minnifield</i>				Date Considered	4-12-05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/643,888
				Filing Date	August 20, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1645
				Examiner Name	Nita M. Minnifield
				Confirmation No.	4642
Sheet	2	of	2	Attorney Docket Number	1954-433

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
		GRATAMA et al., "Diagnostic Potential of Tetramer-based Monitoring of Cytomegalovirus-specific CD8+ T Lymphocytes in Allogeneic Stem Cell Transplantation," <i>Clinical Immunology</i> 106:29-35, 2003.		
		ENGSTRAND et al., "Characterization of CMV pp65-specific CD8+ T Lymphocytes Using MHC Tetramers in Kidney Transplant Patients and Healthy Participants," <i>Transplantation</i> 69(11):2243-2250, 2000.		
		CWYNARSKI et al., "Direct Visualization of Cytomegalovirus-Specific T Cell Reconstitution After Allogeneic Stem Cell Transplantation," <i>Blood</i> 97(5):1232-1240, 2001.		
		EINSELE et al., "Infusion of Cytomegalovirus (CMV)-specific T Cells for the Treatment of CMV Infection Not Responding to Antiviral Chemotherapy," <i>Blood</i> 99(11):3916-3922, 2002.		
		MOSS et al., "Direct Adoptive Transfer of Donor Cytomegalovirus-specific CTL To Transplant Patients Following Selection by HLA-Peptide Tetramers," 12 th Int'l. Cong. Immunol. Montreal, Canada (2004).		
		AUBERT et al., "Cytomegalovirus-Specific Cellular Immune-Responses and Viremia in Recipients of Allogeneic Stem Cell Transplants," <i>J. Infect. Dis.</i> , 184:955-963, 2001.		
		GRATAMA et al., "Tetramer-Based Quantification of Cytomegalovirus (CMV)-Specific CD8+ T Lymphocytes in T-Cell-Depleted Stem Cell Grafts and After Transplantation May Identify Patients At Risk For Progressive CMV Infection," <i>Blood</i> 98(5):1358-1364, 2001.		
		HASSAN-WALKER et al., "CD8+ Cytotoxic Lymphocyte Responses Against Cytomegalovirus After Liver Transplantation: Correlation With Time From Transplant To Recipient of Tacrolimus," <i>J. Infect. Dis.</i> 183:835-843, 2001.		
		Anonymous, Beckman Coulter™ Press Release (2004) "Study suggests Utility of Beckman Coulter iTag™ MHC tetramer technology for predicting development of CMV disease in stem cell transplant patients."		
Examiner Signature			Date Considered	4-12-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

1954-433.1449(3).wpd



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/643,888
Applicant : Don J. DIAMOND
Filed : August 20, 2003
TC/A.U. : 1642
Examiner : Not Yet Assigned

Docket No. : 1954-433
Customer No. : 06449
Confirmation No. : 4642

REGISTRATION DISCLOSURE STATEMENT


Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,
Applicant submits herewith information that the Office may wish
to consider in examination of the subject application. Materials
submitted for consideration are listed on the attached form
PTO-1449.


Respectfully submitted,

By


Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

Enclosure

1954-433.IDS.wpd



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/643,888
				Filing Date	August 20, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	1954-433
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published			T ²
	CC	Altman, John D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:34-39, October 4, 1996.			
	CD	Boppana, Suresh B., et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells," <i>Virology</i> 222 (Article 0124) 293-296, 1996.			
	CE	BenMohamed, Lbachir, et al., "Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted T _H Response," <i>Human Immunology</i> 61:764-779, 2000.			
	CF	Clave, Emmanuel, et al., "Use of a CMV Splice-Specific HLA Tetramer to Select and Expand CMV-Specific CD8+ CTL," Abstract #679, Post Board #-Session 679-1, <i>Blood</i> 94 (10 Suppl. 1):155a, November 15, 1999.			
	CG	LaRosa, C., et al., "Development of In Vitro Stimulation (IVS) Protocol to Measure CMV Specific CTL Activity Using HLA Restricted Specific CTL Epitopes," Abstract #2129, <i>Blood</i> 92 (10 Suppl. 1):518a, 1998.			
	CH	Pande, Hema, et al., "Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus," <i>Proc. Natl. Acad. Sci USA</i> 81: 4965-4969, August 1984.			
	CI	Schutz, Manfred, et al., "Peptide-induced antiviral protection by cytotoxic T Cells," <i>Proc. Natl. Acad. Sci USA</i> Vol. 88: 991-993, February 1991.			
	CJ	Spaete, Richard R., et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage," <i>Virology</i> 167:207-225, 1988.			
	CK	John A. Zala et al., "Status of Cytomegalovirus Prevention and Treatment in 2000," <i>Hematology</i> :339-355, 2000.			
Examiner Signature				Date Considered	4-19-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.